Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

EXEL News and Commentary

Caps

How do you think EXEL will perform against the market?

Add Stock to CAPS Watchlist

All Players

2,475 Outperform
99 Underperform
 

All-Star Players

654 Outperform
23 Underperform
 

Wall Street

8 Outperform
0 Underperform
 

Top EXEL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFBreakerJava (99.77)
Submitted August 04, 2017

After over a decade of R&D, they have a blockbuster cancer drug which has made them profitable and it looks set to have rapidly growing sales in the coming years.Other promising candidates can now be advanced now that the company is making money.

BRADYstocks (47.17)
Submitted February 26, 2008

This sector is a scary one! Fear, though, is a fools game. I don't expect this stock to move upwards in the very near future. The cash burn is, well, similar to that Texas A&M bonfire tradition.

EXEL VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about EXEL.

Recs

1
Member Avatar TMFBreakerJava (99.77) Submitted: 8/4/2017 3:20:28 AM : Outperform Start Price: $25.86 EXEL Score: +0.86

After over a decade of R&D, they have a blockbuster cancer drug which has made them profitable and it looks set to have rapidly growing sales in the coming years.

Other promising candidates can now be advanced now that the company is making money.

Recs

2
Member Avatar EnigmaDude (60.93) Submitted: 12/7/2016 2:08:59 PM : Outperform Start Price: $16.61 EXEL Score: +48.06

May be a bit late but adding today on a nearly 10% drop in price that is based on a tweet from Trump about drug prices.

Recs

1
Member Avatar lifeboy (50.67) Submitted: 10/27/2016 10:06:00 PM : Outperform Start Price: $10.85 EXEL Score: +128.50

They are coming back to earth after a meteoric rise earlier this summer but I still like the basic company over the next year, especially if Gilead buys them out.

Leaderboard

Find the members with the highest scoring picks in EXEL.

Score Leader

beave35

beave35 (96.91) Score: +1,952.09

The Score Leader is the player with the highest score across all their picks in EXEL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Playa14 < 20 12/26/2014 Outperform 5Y $1.27 +2,024.41% +22.95% +2,001.46 0 Comment
beave35 96.91 12/23/2014 Outperform 5Y $1.30 +1,975.22% +23.14% +1,952.09 0 Comment
tomkao < 20 12/15/2014 Outperform 5Y $1.40 +1,827.14% +27.05% +1,800.09 0 Comment
jack0071 72.06 12/3/2014 Outperform 5Y $1.43 +1,786.71% +23.55% +1,763.17 0 Comment
portefeuille 98.72 12/15/2014 Outperform 5Y $1.44 +1,773.61% +26.80% +1,746.81 0 Comment
akoniec 57.94 10/9/2014 Outperform 3Y $1.55 +1,640.65% +30.45% +1,610.20 0 Comment
dcoyne13 48.67 9/16/2014 Outperform 5Y $1.62 +1,565.33% +28.12% +1,537.21 0 Comment
foolerhoff 94.96 1/6/2015 Outperform 5Y $1.64 +1,545.12% +26.73% +1,518.39 0 Comment
new2fool23 48.23 1/5/2015 Outperform 1Y $1.67 +1,515.57% +25.44% +1,490.13 0 Comment
garisonmp3z < 20 1/5/2015 Outperform 5Y $1.67 +1,515.57% +25.44% +1,490.13 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 84.93 7/28/2014 Outperform 3W $4.40 +513.18% +29.48% +483.70 0 Comment
TrackJimCramer 84.93 5/16/2014 Underperform 3W $3.33 +32.13% +5.18% -26.95 7/28/2014 @ $4.40 0 Comment
TrackUltraLong 20.37 12/27/2012 Outperform NS $4.57 +490.37% +80.63% +409.75 1 Comment
TrackJGreenblatt 67.03 4/25/2012 Outperform 1Y $4.85 +2.89% +13.39% -10.51 4/15/2013 @ $4.99 1 Comment
TrackStifel 93.55 3/15/2012 Outperform NS $5.42 +397.79% +82.78% +315.01 0 Comment
TrackPoisedTo < 20 1/10/2012 Outperform 5Y $4.89 +451.74% +97.94% +353.80 0 Comment
TrackJimCramer 84.93 4/26/2011 Outperform 3W $12.35 -73.04% +39.51% -112.55 5/16/2014 @ $3.33 0 Comment
TrackIcahn 91.72 2/24/2009 Outperform 1Y $4.69 +475.27% +246.20% +229.07 1 Comment
trackmerriman 73.71 10/16/2008 Outperform NS $4.15 +71.08% +21.49% +49.60 11/18/2009 @ $7.10 0 Comment
TrackCanaccord 42.53 7/8/2008 Outperform NS $5.19 +12.91% +1.82% +11.08 8/6/2008 @ $5.86 0 Comment
TrackSoros 88.50 3/31/2008 Outperform NS $6.95 +288.20% +101.25% +186.95 1 Comment
TrackEveillard 96.05 12/31/2007 Outperform NS $8.63 +212.63% +82.56% +130.07 1 Comment
TrackLazardCapit 81.07 9/14/2007 Outperform NS $10.44 +158.43% +81.68% +76.75 0 Comment

Featured Broker Partners